Table 1. DCTRN trial participant characteristics.

Patient	Country	Gender	transmission	Age*	Year of HIV Diagnosis	Time before cART(weeks)	Nadir CD4 T cell count before ART	Time on cART (months)	current cART	Time on current cART (months)	Weeks until PVL>1000 c/ml after ATI	visit #8 days from imm #1	visit #11 days from ATI/ imm #4	visit #16 days from ATI	PVL at visit #16 c/ml	weeks off cART (ATI)
H001	BE	male	MSM	45	2001	5	404	64	3TC, AZT, ABC	41	6	ND	7/20	ND	98400	205
H002	NL	male	MSM	36	1992	224	440	121	3TC, AZT, ABC	72	6	64	7/22	53	100000	352
H003	NL	male	MSM	41	2000	32	370	76	3TC, TDF, NVP	28	3	64	7/21	54	100000	28
H004	NL	male	MSM	56	1988	442	400	127	3TC, NVP, AZT	79	4	63	7/21	63	5750	52
H005	NL	male	MSM	42	1993	151	650	133	3TC, NVP, AZT	67	3	63	7/21	56	16800	96
H006	NL	male	MSM	48	1997	2	450	119	3TC, NVP, AZT	67	4	56	7/21	56	14800	96
H007	NL	male	MSM	42	1998	26	340	108	3TC, TDF, NVP	56	8	63	7/23	56	100000	39
H008	NL	male	MSM	45	1997	124	310	91	3TC, NVP, ABC	38	2	63	7/21	54	43600	28
H009	BE	male	MSM	52	1991	248	326	142	3TC, NVP, ddI	47	4	ND	7/24	53	9300	181
H010	BE	male	MSM	45	1992	442	323	75	TDF, EFZ, ddI	43	6	ND	7/21	ND	100000	94
H011	BE	male	MSM	55	2001	25	555	69	3TC, AZT, ABC	52	6	ND	7/20	56	149	137
H012	BE	male	MSM	39	1993	423	304	73	TDF, EFZ, d4T	48	3	ND	7/22	54	27700	90
H013	BE	male	MSM	72	2000	27	660	78	3TC, NVP, AZT	65	6	ND	7/21	56	20000	179
H014	NL	male	MSM	37	1996	30	300	128	3TC, TDF, NVP	38	3	64	7/21	55	91200	29
H015	NL	male	MSM	42	2004	30	290	36	3TC, TDF, NVP	35	6	64	7/20	56	12600	50
H016	NL	male	MSM	56	1995	11	350	142	3TC, TDF, NVP	61	6	61	14/27	63	58000	117
H017	NL	male	MSM	50	1999	245	350	45	3TC, TDF, NVP	42	2	63	7/19	54	100000	50

* at immunization #1

MSM: men having sex with men